Citius Pharmaceuticals Stock Price - CTXR

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 1.16 ▲ 0.02 (1.75%)
Company Name Stock Ticker Symbol Market Type
Citius Pharmaceuticals Inc CTXR NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.01 -0.87% 1.14 1.45 1.12 1.18 1.15 19:59:26
Bid Price Ask Price Spread Spread % News
1.16 1.27 0.11 8.66% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8,051 3,020,842 $ 1.29 $ 3,899,154 604,775 0.40 - 1.63
Last Trade Time Type Quantity Stock Price Currency
19:59:26 formt 257 $ 1.16 USD

Citius Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 32.98M 28.93M $ -12.54M -0.78 - 16.62M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 12.00 42.70%

more financials information »

Citius Pharmaceuticals News

Loading Messages....

Latest CTXR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CTXR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.8341.450.821.05695,9290.30636.69%
1 Month0.621.450.570.9600043882,6370.5283.87%
3 Months0.58851.450.400.821145426,9270.551593.71%
6 Months1.021.500.400.8368751276,0190.1211.76%
1 Year1.151.630.400.9440786214,447-0.01-0.87%
3 Years3.405.490.401.53144,000-2.26-66.47%
5 Years3.405.490.401.53144,000-2.26-66.47%

Citius Pharmaceuticals Description

Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections. The company's Hydrocortisone-Lidocaine provides anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. The company is primarily operating within the critical care and cancer care market segments.

Your Recent History
Citius Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.